Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12859646 | 1.00 | CYP19A1 (0.41) | CYP19A1HTTCA1CA2CA4 | |
| SCHEMBL12464963 | 1.00 | CYP19A1 (0.41) | CYP19A1HTTCA1CA2CA4 | |
| SCHEMBL13176769 | 0.94 | HTT (0.47) | CYP19A1HTTCA1CA2CA4 | |
| SCHEMBL11884817 | 0.91 | CYP19A1 (0.41) | CYP19A1HTTCA1CA2CA4 | |
| Ethylene SCHEMBL27701965 | 0.83 | HTT (0.46) | CYP19A1HTTCA1CA2CA4 | |
| SCHEMBL15564163 | 0.80 | — | — | |
| SCHEMBL13801516 | 0.77 | CYP19A1 (0.39) | CYP19A1HTTCA1CA2CA4 | |
| SCHEMBL9738461 | 0.74 | — | — | |
| SCHEMBL13259635 | 0.72 | TRPA1 (0.36) | CYP19A1TRPA1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2677519 | 0.71 | CYP2D6 (0.33) | CYP19A1HTTCYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486441-A1 | SILA-ANALOGUES OF VITAMIN D COMPOUNDS, METHOD OF PRODUCING SAID COMPOUNDS AND USES THEREOF | REQUIMTE - Rede de Química e Tecnologia (PT) | 2025-01-08 | — | — | EP | disclosed |
| CN-115947678-B | Synthesis method of stable isotope 2H (D) marked 25-hydroxy vitamin D2 | 成都诺森医学检验有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023161688-A1 | SILA-ANALOGUES OF VITAMIN D COMPOUNDS, METHOD OF PRODUCING SAID COMPOUNDS AND USES THEREOF | REQUIMTE - REDE DE QUÍMICA E TECNOLOGIA (PT) | 2023-08-31 | — | — | WO | disclosed |
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2008-11-13 | — | — | US | disclosed |
| EP-1622455-A2 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | Bioxell S.p.a. (IT) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004098522-A2 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2004-11-18 | — | — | WO | disclosed |
| EP-0647219-A1 | DERIVATIVES IN THE VITAMIN D SERIES MODIFIED AT THE 20 POSITION, A METHOD OF PREPARING SUCH DERIVATIVES, INTERMEDIATES USED IN THIS METHOD, PHARMACEUTICAL PREPARATIONS CONTAINING THE DERIVATIVES AND THEIR USE IN THE PREPARATION OF DRUGS. | SCHERING AG (DE) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000428-A1 | DERIVATIVES IN THE VITAMIN D SERIES MODIFIED AT THE 20 POSITION, A METHOD OF PREPARING SUCH DERIVATIVES, INTERMEDIATES USED IN THIS METHOD, PHARMACEUTICAL PREPARATIONS CONTAINING THE DERIVATIVES AND THEIR USE IN THE PREPARATION OF DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | VDR, GC, CYP24A1 | CYP19A1 342/4885HTT 1891/4885CA1 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.